Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Triple Negative Breast Cancer
Related studies linked through entity extraction aliases.
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Status
- RECRUITING
- Phase
- PHASE1
A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE2
Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
- Status
- COMPLETED
- Phase
- PHASE1
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study
- Status
- UNKNOWN
- Phase
- PHASE2
Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC
- Status
- COMPLETED
- Phase
- PHASE2
Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI)
- Status
- RECRUITING
- Phase
- EARLY_PHASE1
Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC
- Status
- UNKNOWN
- Phase
- PHASE2
CMP-001 and Pre-operative Stereotactic Body Radiation Therapy (SBRT) in Early Stage Triple Negative Breast Cancer (TNBC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
MicroRNA Profiles in Triple Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Imaging Performance Assessment of 89Zi-girentuximab (89Zr-TLX250) PET in Metastatic Triple Negative Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2